Navigation Links
Cancer and arthritis therapy may be promising treatment for diabetes
Date:12/18/2007

New Haven, Conn.An antibody used to treat certain cancers and rheumatoid arthritis appears to greatly delay type 1 diabetes in mice, Yale School of Medicine researchers report in the Journal of Clinical Investigation.

Even better, the beneficial effects of the antibody continue to be observed long after the antibody is no longer administered, the researchers said.

The antibody, rituximab (anti-CD20), depletes B cells. Experimental evidence in mutant mice indicates that B cells play a role in autoimmune diseases by interacting with T cells of the immune system. It is T cells that destroy insulin-producing cells directly in the pancreas, leading to type 1 diabetes.

Our paper shows, for the first time, that after successful B cell depletion, regulatory cells emerge that can continue to suppress the inflammatory and autoimmune response even after the B cells return, said Li Wen, senior research scientist in the division of endocrinology. Even more strikingly, we found that these regulatory cells include both B and T cells.

To determine if B cell depletion would work as a therapy for type 1 diabetes, Wen and her colleague at Yale, Mark Shlomchik, M.D., professor of laboratory medicine and immunobiology, developed a mouse model. They engineered mice that were predisposed to diabetes and had the human version of CD20, the molecule rituximab targets, on the surface of their B cells.

The researchers tested a mouse version of the drug to deplete B cells in mice either before diabetes onset, or within days of diagnosis with diabetes. The drug treatment significantly delayed diabetes onset in pre-diabetic mice. This translated to a 10- to 15-week delay in developing diabetes compared to mice given a sham treatment. The equivalent period for humans would be approximately 10 to 15 years. Of the 14 mice that already had diabetes, five stopped needing insulin for two to five months while all the sham-treated mice remained dia
'/>"/>

Contact: Jacqueline Weaver
jacqueline.weaver@yale.edu
203-432-8555
Yale University
Source:Eurekalert

Page: 1 2

Related biology news :

1. Green tea boosts production of detox enzymes, rendering cancerous chemicals harmless
2. A study by the MUHC and McGill University opens a new door to understanding cancer
3. ESF EURYI award winner aims to stop cancer cells reading their own DNA
4. Protein chatter linked to cancer activation
5. Newly created cancer stem cells could aid breast cancer research
6. Western diet linked to increased risk of colon cancer recurrence
7. Obesity and lack of exercise could enhance the risk of pancreatic cancer
8. Low levels of key protein may indicate pancreatic cancer risk
9. Birth records hold pancreatic cancer clue
10. Many parents at-risk for cancer disclose genetic test results to children
11. A new radiation therapy treatment developed for head and neck cancer patients

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)... Iowa - The only swine vaccine available for the H...infected with the virus. The vaccination marks the...diagnosed with the pandemic flu., Iowa State Uni..., developed the vaccine this summer and has been s...a, Kansas and Illinois for several weeks., The l...
(Date:11/23/2009)...GN, Ill. Two new studies reveal in unprecedented ...ules to assemble new proteins and guide them towar...es used molecular dynamics flexible fitting (MDFF)...wo prominent molecular partners. , The first st...iences , concerns the intimate signaling between t...
(Date:11/23/2009)...ional Institute of General Medical Sciences (NIGMS..., is investing $42.3 million for grants in scienti...O)." NIH developed the GO grant program to stimula... provided by the American Recovery and Reinvestmen...ects that promise to have a significant impact on ...
Breaking Biology News(10 mins):Iowa State researcher produces, ships only H1N1 vaccine available for swine 2Computational microscope peers into the working ribosome 2Computational microscope peers into the working ribosome 3NIGMS invests in scientific Grand Opportunities with Recovery Act funds 2NIGMS invests in scientific Grand Opportunities with Recovery Act funds 3Platelet Rich Plasma 3A Does It Work 3F 58657 1Platelet Rich Plasma 3A Does It Work 3F 58657 2Platelet Rich Plasma 3A Does It Work 3F 58657 3Platelet Rich Plasma 3A Does It Work 3F 58657 4DST Systems Inc Announces Exchange Transaction Involving 4 125 25 Series A Convertible Senior Debentures 58653 1DST Systems Inc Announces Exchange Transaction Involving 4 125 25 Series A Convertible Senior Debentures 58653 2Medicago begins human clinical testing with its avian flu pandemic vaccine 14315 1Medicago begins human clinical testing with its avian flu pandemic vaccine 14315 2
...urned on to target and destroy foreign infectious ...n, it is just as important to turn the immune syst.... The fruit fly Drosophila has served as a good mo..., pointing to conserved pathways and mechanisms. R...more subtly regulated and produces a wider range o...
...ld at the University of Edinburgh, 3-6 September 2... fingers, faeces and flies: food and waterborne pa...s. , Hepatitis E virus (HEV), which can be fatal,...veloping countries but scientists in the Netherlan...e contracting the virus from pork. It is one of fe...
...els in coastal waters interfere with fish reproduc...cientist from The University of Texas at Austin Ma...seasonal low levels of oxygen, known as hypoxia, h...ghout the world over the past few decades, largely...ultural and industrial activities. Hypoxias long-t...
Other Biology News:Society for General Microbiology 161st Meeting, University of Edinburgh 2Low oxygen in coastal waters impairs fish reproduction 2
(Date:11/24/2009)... Health care employment grew by 29,000 jobs in Oc...consistent growth during the U.S. recession. Howev...ble, and health systems are coming closer to havin...st administrators. , (Voc...ntinued growing in October despite the shedding of...
(Date:11/24/2009)...Newswire-Asia/--ShanghaiBiolaxyannouncedthe,Chines...the,investigationalnewdrugapplication(IND)foritsor...lationtotreatdiabetes.ThisIND,approvalallowsBiolax...betesisadisordercharacteristicofhighbloodglucosean...sultinseveremicro-and,macro-vasculardiseases,losso...
(Date:11/24/2009)..., TORONTO,Nov.24/PRNewswire-FirstCall/-HamiltonT...eadingproviderofadvancedlasersystemsandinstruments...dayreportedoperationalandfinancialresultsforthethi...ts,-Revenuewas$1.46millioncomparedwith$1.43millio...with66.1percentinQ3,2008,-Netlossreducedto$148,000...
(Date:11/24/2009)...er24/PRNewswire/--HealthRoboticstodayannounced,tha...lected,investors.ThisrecentlyformedToronto-basedco...Inc.andwillmarket,install,andsupport,HealthRobotic...lutionaryproductofferingsi.v.STATION(TM),i.v.SOFT(...ovideassistanceonan"asneeded,basis"toitsstrategicp...
Breaking Biology Technology:The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4Biolaxy Secures IND Approval for Oral Insulin 2Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2
...AN DIEGO, Sept. 10 ADVENTRX Pharmaceuticals,Inc. ...elopment company,focused on commercializing propri...er and infectious diseases, announced today that i... Drug Administration (FDA) regarding its,proposed ...th for ANX-514,(docetaxel emulsion). The FDA has i...
...ompany to Hold a Conference Call Tomorrow (Tuesday...the Clinical Trial, Valley Cottage, NEW YORK, Sep...TLB ; LSE: XTL; TASE: XTL) today announced,the ini...e - a serotonin,and norepinephrine reuptake inhibi...thic pain. Bicifadine is being developed for the ...
...OUTH SAN FRANCISCO, Calif., Sept. 7 Monogram,Bios...t William D. Young, CEO,and Chairman, is scheduled...y Partners, G5: The Growth Conference on Monday, S...a.m. Pacific Time) at the St. Regis,Hotel in San F...oadcast or the subsequent archived,recording, log ...
Other Biology Technology:ADVENTRX Announces ANX-514 Clinical Development Plan Affirmed by the FDA 2ADVENTRX Announces ANX-514 Clinical Development Plan Affirmed by the FDA 3ADVENTRX Announces ANX-514 Clinical Development Plan Affirmed by the FDA 4XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 2XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 3XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 4XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 5XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 6XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 7Monogram Biosciences to Present at the ThinkEquity Partners' Fifth Annual Growth Conference 2
Human Antibody Array I Kit, RayBio L Series 507: RayBio Label-based from Raybiotech, Inc.
Mouse Anti-Human HVEM Cell Surface Staining Monoclonal Antibodies, Allophycocyanin Conjugated, 94801 from R&D Systems
... Osmometer for 10 L sample. Ideal for small volum...iatric, general adult, veterinary and experimental...selected values. Includes built-in printer, keypa...-keeping. Optional barcode scanner available. RS...
Rabbit Anti-Human UCP2 Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Biology Products: